Genmab A/S Discloses Managerial Share Transactions Following RSU Vesting

On April 1, 2026, Genmab A/S filed a Form 6-K disclosing transactions in shares and linked securities by its managerial employees and their closely associated persons. The transactions primarily involved the acquisition of shares resulting from the vesting of restricted stock units (RSUs) granted on March 29, 2023. Key executives participating in the vesting and net settlement included Jan van de Winkel (President & CEO), who acquired 8,525 shares; Anthony Pagano (EVP & CFO), who acquired 4,206 shares; and Tahamtan Ahmadi (EVP & CMO), who acquired 5,186 shares. Other executives involved in the vesting included Martine van Vugt, Christopher Cozic, and Judith Klimovsky. All transactions were conducted outside the market at a price of DKK 1,758.50 per share. These disclosures are made in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse. The filing does not report any changes to the company's clinical pipeline or financial guidance.